{"schemaVersion":"cwiki-fiche-1.0","identifiers":{"inchiKey":"WQJZGZRGXVDCJN-FOWTUZBSSA-N","prefName":"Cannabigerol quinone","symbol":"CBGQ","iupacName":"2-[(2E)-3,7-dimethylocta-2,6-dienyl]-3-hydroxy-5-pentylcyclohexa-2,5-diene-1,4-dione","aliases":["CBGQ","Cannabigérol quinone","Cannabigeroquinone","VCE-003","Quinone du cannabigérol"],"cas":null,"pubchemCid":"53377584","chebiId":null,"smiles":"CCCCCC1=CC(=O)C(=C(C1=O)O)C/C=C(\\C)/CCC=C(C)C","molecularFormula":"C21H30O3","molecularWeight":330.5,"xrefs":{"pubchem":"https://pubchem.ncbi.nlm.nih.gov/compound/53377584"}},"classification":{"family":"semisynthetique","familyLabel":"Semi-synthetic cannabinoid","origin":"semisynthetic","originLabel":"Semi-synthétique","structuralClassFr":null},"originSynthesis":{"heading":"Route of preparation (chemical process)","summaryFr":"Route of preparation: cannabigerol quinone derives from CBG by oxidation of the resorcinol core. This is a chemical transformation of the oxidation class, not an enzymatic pathway described in the plant.","originNote":"An oxidation product of cannabigerol: the resorcinol core of CBG is converted into a hydroxyquinone. It was studied under the code VCE-003 by Spanish and Italian teams and served as the starting point for non-thiophilic derivatives such as VCE-003.2.","discovered":""},"pharmacology":{"summaryFr":"Cannabigerol quinone (CBGQ, VCE-003) is the oxidation product of the resorcinol core of CBG. It was reported in 2012 by Granja and colleagues, who were studying the effect of this oxidation on affinities for CB1, CB2 and PPARγ. The compound activates PPARγ transcriptional activity, protects neurons from excitotoxicity and curbs the release of pro-inflammatory mediators by microglia. In the Theiler's virus mouse model of multiple sclerosis, it improved motor performance and reduced microglial reactivity. The quinone then served as the basis for derivatives, including VCE-003.2, evaluated in experimental models of Huntington's disease, Parkinson's disease and amyotrophic lateral sclerosis. No human data exist for VCE-003 itself.","receptorSummaryFr":"The 2012 study examined the effect of oxidising cannabigerol on affinities for CB1, CB2 and the nuclear receptor PPARγ, and singled out the quinone as an anti-inflammatory agent. VCE-003 activates PPARγ transcriptional activity, protects neuronal cells from excitotoxicity and inhibits the release of pro-inflammatory mediators by microglial cells stimulated with lipopolysaccharide. Later work focused on its derivative VCE-003.2, described as a PPARγ ligand.","binding":[{"target":"PPARγ","efficacy":"full_agonist","relativeActivity":60,"reported":"active l'activité transcriptionnelle de PPARγ (Granja et coll., 2012) ; aucune constante reprise ici","confidence":"medium"}],"references":[{"label":"Granja et coll., une quinone du cannabigérol atténue la neuro-inflammation dans un modèle chronique de sclérose en plaques, Journal of Neuroimmune Pharmacology 2012","pmid":"22971837","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/22971837/"},{"label":"Díaz-Alonso et coll., VCE-003.2, nouveau dérivé du cannabigérol, favorise la survie des progéniteurs neuronaux et atténue la symptomatologie dans des modèles murins de maladie de Huntington, Scientific Reports 2016","pmid":"27430371","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/27430371/"},{"label":"Légifrance, annexe IV de l'arrêté du 22 février 1990 fixant la liste des substances classées comme stupéfiants","pmid":null,"doi":null,"url":"https://www.legifrance.gouv.fr/loda/article_lc/LEGIARTI000020689963/"},{"label":"PubChem CID 53377584 : cannabigéroquinone (identifiants)","pmid":null,"doi":null,"url":"https://pubchem.ncbi.nlm.nih.gov/compound/53377584"}]},"pharmacokinetics":null,"metabolism":null,"detection":null,"subjectiveEffects":{"profile":[{"key":"calm","label":"Calm","description":"Relaxation of body and mind; reduced mental noise without marked drowsiness.","intensity":6},{"key":"focus","label":"Clarity","description":"Sustained attention and clear thinking; functional lucidity, not euphoria.","intensity":4},{"key":"sleep","label":"Sleep","description":"Sedative effect: aids sleep onset and the continuity of deep sleep.","intensity":4},{"key":"appetite","label":"Appetite","description":"Stimulation of hunger and of taste appreciation (the “munchies” effect).","intensity":4},{"key":"uplift","label":"High","description":"Euphoria and sensory intensity; altered perception of time and space.","intensity":2}],"doseRanges":null,"humanDataCharacterised":false},"indications":{"approvedMedicines":[]},"harmProfile":{"unstudiedBanner":true,"bannerTextFr":"Aucune dose humaine caractérisée : données animales / in vitro uniquement. Profil d'effet, marge de sécurité et toxicité aiguë non documentés en clinique humaine.","toxicologyFr":null},"legal":{"scheduleStatus":"unscheduled","scheduleLabel":"Unscheduled","frScheduleStatus":"unscheduled","tiers":[{"jurisdiction":"international","jurisdictionLabel":"International","label":null,"reference":null,"url":null,"effectiveDate":null,"lastVerified":"2026-05-01","supersededBy":null},{"jurisdiction":"eu","jurisdictionLabel":"Union européenne","label":"No control measure of its own at European Union level. The molecule appears in no schedule of the 1961 Convention on Narcotic Drugs or of the 1971 Convention on Psychotropic Substances. It holds no marketing authorisation and no novel food authorisation under Regulation (EU) 2015/2283: it circulates only as a chemical or reference standard intended for research.","reference":null,"url":null,"effectiveDate":null,"lastVerified":"2026-05-01","supersededBy":null},{"jurisdiction":"fr","jurisdictionLabel":"France","label":"Unscheduled substance. Cannabigerol quinone is named in no annex of the order of 22 February 1990 and falls under no generic clause: it is not a tetrahydrocannabinol and it lacks the benzo[c]chromene nucleus targeted by the ANSM decision of 22 May 2024. This absence of scheduling is not an authorisation: the molecule is neither an authorised medicine nor an ingredient permitted in food or cosmetics.","reference":null,"url":null,"effectiveDate":null,"lastVerified":"2026-05-01","supersededBy":null}],"sourcesFr":"EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA."},"references":[{"label":"Granja et coll., une quinone du cannabigérol atténue la neuro-inflammation dans un modèle chronique de sclérose en plaques, Journal of Neuroimmune Pharmacology 2012","pmid":"22971837","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/22971837/"},{"label":"Díaz-Alonso et coll., VCE-003.2, nouveau dérivé du cannabigérol, favorise la survie des progéniteurs neuronaux et atténue la symptomatologie dans des modèles murins de maladie de Huntington, Scientific Reports 2016","pmid":"27430371","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/27430371/"},{"label":"Légifrance, annexe IV de l'arrêté du 22 février 1990 fixant la liste des substances classées comme stupéfiants","pmid":null,"doi":null,"url":"https://www.legifrance.gouv.fr/loda/article_lc/LEGIARTI000020689963/"},{"label":"PubChem CID 53377584 : cannabigéroquinone (identifiants)","pmid":null,"doi":null,"url":"https://pubchem.ncbi.nlm.nih.gov/compound/53377584"}],"meta":{"slug":"cbgq","url":"https://en.phytogrammes.com/wiki/cbgq","lastVerified":"2026-05-01","dataUpdatedAt":"2026-10-11","confidence":"high","dataCompletenessPct":90,"disclaimerFr":"Contenu éditorial informatif, sans valeur d'avis médical ni juridique. Sources primaires citées par fiche. Réservé aux adultes."}}